Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Amarin Corporation plcNASDAQ: AMRN

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 5.1% from a year ago

Total equity stood at $449.41M at the end of Q1 FY2026, down 5.1% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at -8.3% a year.

Context

  • Total equity amounted to 69.6% of total assets at the end of Q1 FY2026, down 2.6 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -5.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$449.41M-2.1% QoQ
Last fiscal yearDec 2025
$459.28M-5.5% YoY
Year agoMar 2025
$473.69M-5.1% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.1%——
1 year-5.5%——
3-year CAGR-8.3%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
459.28M USD
Year-over-year change
-5.5%
4-year CAGR
-8.9%

Total Equity vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -5.1% is the 7th highest of 11, against a peer median of +10.9%.
  • Total equity amounts to 69.6% of total assets for AMRN, versus a peer median of 76.9%.
AMRN Competitors
Total Equity for AMRN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AMRNAmarin Corporation plcMar 2026$449.41M USD-5.1%-8.3%69.6%
ALTAltimmune, Inc.Mar 2026$283.99M USD+99.8%+6.7%84.6%
LYELLyell Immunopharma, Inc.Mar 2026$273.67M USD-18.7%-33.2%78.1%
ENGNenGene Holdings Inc.Apr 2026$255.17M USD+12.3%+9.6%83.0%
ANROAlto Neuroscience, Inc.Mar 2026$243.37M USD+75.0%—88.1%
DBVTDBV Technologies S.A.Mar 2026$207.9M USD+7136.3%-4.6%78.0%
LRMRLarimar Therapeutics, Inc.Mar 2026$158.03M USD+9.5%-11.0%75.8%
KRROKorro Bio, Inc.Mar 2026$119.63M USD-13.9%—65.2%
CLLSCellectis S.A.Mar 2026$59.92M USD-48.4%-15.5%20.7%
SLNSilence Therapeutics plcMar 2026$49.4M USD+143.8%+41.3%42.9%
ACIUAC Immune S.A.Mar 2026CHF 31.53M CHF-66.7%-35.7%22.9%
Peer median (excluding AMRN) —+10.9%-7.8%76.9%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents219.45M217.67M199.25M121.04M134.86M
Short-term Investments234.67M91.7M121.41M173.18M167.93M
Net Receivables163.65M130.99M133.56M122.28M126.83M
Inventory234.68M228.73M258.62M166.05M195.91M
Other Current Assets3.92M20.02M525K12.85M24.35M
Total Current Assets878.73M689.1M724.98M595.4M649.88M
Property, Plant & Equipment (Net)9.09M9.95M8.42M7.61M6.47M
Goodwill000013.36M
Intangible Assets23.55M21.78M19.3M16.39M0
Long-term Investments35M1.28M000
Tax Assets00000
Other Non-current Assets121.71M164.08M78.98M65.95M1.06M
Total Non-current Assets189.34M197.08M106.7M89.95M20.89M
Total Assets1.07B886.18M831.68M685.35M670.77M
Account Payables114.92M64.6M52.76M40.37M45.35M
Short-term Debt00000
Tax Payables00000
Deferred Revenue2.65M2.2M2.34M00
Other Current Liabilities45.6M35.64M185.23M17.55M149.1M
Total Current Liabilities370.68M259.48M259.28M179.95M194.46M
Long-term Debt00006.08M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)14.06M13.15M2.51M00
Other Non-current Liabilities7.65M8.21M9.06M11.5M4.87M
Total Non-current Liabilities30.28M31.37M20.31M19.22M17.03M
Total Liabilities400.97M290.85M279.59M199.17M211.49M
Common Stock294.03M299M302.76M305.3M310.18M
Retained Earnings(1.42B)(1.53B)(1.59B)(1.67B)(1.71B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity667.1M595.33M552.1M486.18M459.28M
Total Debt8.58M10.02M8.74M7.72M12.16M
Net Debt(210.88M)(207.65M)(190.52M)(113.32M)(122.7M)

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.